 |
38 Diseases |  |
10 Trials |
|
10 Trials |  |
381 News |  |
| «1234 |
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Retrospective data, Review, Journal: The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. (Pubmed Central) - Aug 2, 2019
Rebamipide mouthwash is effective in the prevention of severe mucositis and stomatitis. However, evaluation of adverse events in observational studies are needed.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers. (Pubmed Central) - Jul 11, 2019
No local or systemic side effects were noted. The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Journal: Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. (Pubmed Central) - Jul 3, 2019
The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers. We discovered a previously unknown phenomenon of the disaccharidases activity increase in duodenal mucosa and improved carbohydrates tolerance in the patients with EIMD taking Rebamipide in the dose 300 mg/day for 12 weeks.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Review, Journal: Effect of N-acetylcysteine on mucosal immunity of respiratory tract. (Pubmed Central) - Jun 19, 2019
The outcome of diseases accompanied or caused by mucostasis depends both on the restoration of drainage function of the airways and on the effectiveness of immune mechanisms against pathogens...There was no convincing evidence that NAC is able to suppress any component of mucosal immunity. For final conclusions on this subject, further research are required.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Tracheobronchomalacia and Excessive Dynamic Airway Collapse: Medical and Surgical Treatment. (Pubmed Central) - Jun 15, 2019
Excessive central airway collapse (ECAC) is characterized by excessive narrowing of the airway lumen during exhalation leading to dyspnea, cough, mucostasis, recurrent respiratory infections, and poor quality of life...A short-term stent trial in selected patients with severe symptomatic ECAC is needed to assess whether patients will have improvement in symptoms and thus identify patients who will benefit from surgical central airway stabilization. A multidisciplinary airway team in highly specialized centers with experience in the evaluation and treatment of this patient population is essential for optimal outcomes.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Journal: Effect of mucostatic and selective pressure impression techniques on residual ridge resorption in individuals with different bone mineral densities: A prospective clinical pilot study. (Pubmed Central) - Jun 5, 2019
A multidisciplinary airway team in highly specialized centers with experience in the evaluation and treatment of this patient population is essential for optimal outcomes. Mandibular residual ridge resorption was reduced for dentures fabricated using the mucostatic impression technique compared with the selective pressure impression technique in individuals with diminished bone density.
- || Mucosta oral (rebamipide oral) / Otsuka, Acucela
Mucosta - API Insight, 2019 - https://t.co/guyiBzPH8C https://t.co/zfyWYdINCk (Twitter) - May 31, 2019
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Retrospective data, Journal: The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. (Pubmed Central) - May 30, 2019
Mandibular residual ridge resorption was reduced for dentures fabricated using the mucostatic impression technique compared with the selective pressure impression technique in individuals with diminished bone density. In the clinical trial for the treatment of oral mucositis, it was strongly suggested that objective evaluation with a consistent scale would be required.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: BST-104, a Water Extract of Lonicera japonica, Has a Gastroprotective Effect via Antioxidant and Anti-inflammatory Activities. (Pubmed Central) - May 24, 2019
...After orally administering BST-104, chlorogenic acid, rebamipide (positive control), or vehicle to each animal model, gastric lesion sizes, gastric mucus statuses, proinflammatory cytokine levels, and oxidative stress were measured...In addition, BST-104 significantly suppressed proinflammatory cytokine (tumor necrosis factor-α, interleukin [IL]-6, and IL-1β) increases, and real-time PCR showed that BST-104 significantly downregulated NF-κB expression. In summary, BST-104 and its active component, chlorogenic acid, were found to have gastroprotective effects by virtue of their antioxidant and anti-inflammatory properties through downregulation of NF-κB expression.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Contact Lens-Associated Dry Eye Disease: Recent Advances Worldwide and in Japan. (Pubmed Central) - May 18, 2019
However, the effects of contact lens properties on the tear film and ocular surface are still unclear. Further controlled studies are needed in the future.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Medical Treatment for Dry Eye in Japan. (Pubmed Central) - May 18, 2019
Moreover, Diquas has also been launched in other Asian countries, such as Korea, Thailand, and Vietnam. This report summarizes the efficacy and characteristics of these two eye drops to improve our understanding of dry eye.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Secreted Mucins on the Ocular Surface. (Pubmed Central) - May 18, 2019
However, it is unknown whether changes in mucin expression on the ocular surface cause or result from dry eye. Further study is needed to determine the true mechanism of dry eye disease.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Preclinical, Journal: Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats. (Pubmed Central) - May 16, 2019
Therefore, the anti-PD effect of rebamipide may involve stabilization of mitochondrial bioenergetics, enhancement of GCase enzymatic activity as well as decreased oxidative stress with α-synuclein pathology, and apoptosis in 6-OHDA-induced hemiparkinson's rat model. Hence, preclinical evidence indicates rebamipide to be a potential drug for management of PD.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Combination therapy: The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=153, Completed, Sponsor: Yonsei University
Hence, preclinical evidence indicates rebamipide to be a potential drug for management of PD. Recruiting --> Completed
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: Characterization of Amorphous Solid Dispersion of Pharmaceutical Compound with pH-Dependent Solubility Prepared by Continuous-Spray Granulator. (Pubmed Central) - Apr 18, 2019
...Rebamipide (RBM), a biopharmaceutical classification system class IV drug, that has low solubility or permeability in the stomach, was selected as a model compound...The carboxy group of RBM was ionized in the granules and interactions appeared between RBM and PVP-VA, with the formation of an ASD confirmed and the solubility was enhanced compared with bulk RBM crystals. The SGR methodology has the possibility of contributing to process development in the pharmaceutical industry.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Clinical, Journal: Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. (Pubmed Central) - Apr 5, 2019
The inclusion of rebamipide in the classical triple scheme of H. pylori ET increases the effectiveness of treatment and does not affect the safety profile. In the post-eradication period, it is advisable to continue the use of rebamipide to potentiate the repair of the gastric mucosa and regress the inflammatory processes.
- | Mucosta oral (rebamipide oral) / Otsuka, Acucela
Journal: NSAIDs and the small bowel. (Pubmed Central) - Apr 3, 2019
If NSAID cessation is not possible, COX-2 inhibition without PPI therapy should be considered in patients with upper gastrointestinal risk factors. Mucoprotective agents such as misoprostol and rebamipide show promise and probiotics may have a future role.
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet (clinicaltrials.gov) - Oct 31, 2018
P2, N=250, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Mucoprotective agents such as misoprostol and rebamipide show promise and probiotics may have a future role. Active, not recruiting --> Completed
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment closed: Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet (clinicaltrials.gov) - Oct 9, 2018
P2, N=250, Active, not recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P3 trial: Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions (clinicaltrials.gov) - Sep 5, 2018
P3, N=32, Completed, Sponsor: Galeno Desenvolvimento de Pesquisas Clínicas
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P2 trial: Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet (clinicaltrials.gov) - Feb 19, 2018
P2, N=250, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Journal: Oxidative stress from reflux esophagitis to esophageal cancer; the alleviation with antioxidants. (Pubmed Central) - Feb 27, 2017
Also, since there is great interest in complete healing of reflux esophagitis and chemoprevention to prevent or slow malignant transformation, the contribution of antioxidants or antioxidative agents, which was delivered during SFRR-Asia 2015 (Chiangmai, Thailand), will be described. Also, the molecular mechanisms how the antioxidative drugs, rebamipide, ecabet sodium, and pantoprazole exerted significant protection from acids or bile acids-associated esophagitis are included.
- |||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Trial primary completion date: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - May 2, 2016
P2, N=94, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Also, the molecular mechanisms how the antioxidative drugs, rebamipide, ecabet sodium, and pantoprazole exerted significant protection from acids or bile acids-associated esophagitis are included. Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial: REPAIR: A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (clinicaltrials.gov) - May 2, 2016
P4, N=143, Completed, Sponsor: YongChan Lee
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial primary completion date: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Apr 4, 2016
P2, N=90, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015 Trial primary completion date: Feb 2016 --> May 2016
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment open, Trial primary completion date, Combination therapy: Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia (clinicaltrials.gov) - Jan 5, 2016
P4, N=200, Recruiting, Sponsor: University of Malaya
Trial primary completion date: Feb 2016 --> May 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial primary completion date: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Dec 21, 2015
P2, N=90, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Nov 2015 --> Feb 2016
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P1 trial: Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo (clinicaltrials.gov) - Dec 17, 2015
P1, N=24, Completed, Sponsor: Biolab Sanus Farmaceutica
- || Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial primary completion date: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=90, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Trial primary completion date: Nov 2015 --> Feb 2016 Trial primary completion date: Aug 2015 --> Nov 2015
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Trial primary completion date: Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? (clinicaltrials.gov) - Sep 5, 2015
P=N/A, N=290, Completed, Sponsor: Kangdong Sacred Heart Hospital
Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Dec 2010
- ||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment closed: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - May 14, 2015
P2, N=90, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Dec 2010 Recruiting --> Active, not recruiting
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial: Clinical Effect of Rebamipide on Chronic Gastritis (clinicaltrials.gov) - Mar 19, 2015
P4, N=180, Completed, Sponsor: BangMao Wang
- Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Combination therapy: The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=218, Recruiting, Sponsor: Yonsei University
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial, Combination therapy: Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia (clinicaltrials.gov) - May 7, 2014
P4, N=200, Not yet recruiting, Sponsor: University of Malaya
- |||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment open: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Apr 16, 2014
P2, N=90, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P1 trial: A Drug Interaction Study of Mosapride and Rebamipide (clinicaltrials.gov) - Apr 6, 2014
P1, N=40, Completed, Sponsor: IlDong Pharmaceutical Co Ltd
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: A Drug Interaction Study of Mosapride and Rebamipide (clinicaltrials.gov) - Apr 2, 2014
P1, N=40, Completed, Sponsor: IlDong Pharmaceutical Co Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P2 trial: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Mar 10, 2014
P2, N=90, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
- |||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Head-to-Head: A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab. (clinicaltrials.gov) - Nov 4, 2013
P4, N=258, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
Not yet recruiting --> Completed Recruiting --> Completed
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Enrollment change: Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis (clinicaltrials.gov) - May 13, 2013
P3, N=55, Completed, Sponsor: PT Otsuka Indonesia
Recruiting --> Completed N=45 --> 55
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis (clinicaltrials.gov) - May 13, 2013
P3, N=55, Completed, Sponsor: PT Otsuka Indonesia
N=45 --> 55 Recruiting --> Completed
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P4 trial, Head-to-Head: A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab. (clinicaltrials.gov) - Mar 21, 2013
P4, N=258, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
- |||||||||| recoflavone (DA-6034) / GL PharmTech
New P3 trial, Head-to-Head: A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 (clinicaltrials.gov) - Mar 17, 2013
P3, N=492, Recruiting, Sponsor: Dong-A Pharmaceutical Co., Ltd.
- ||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial initiation date, Combination therapy: MGES: Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation (clinicaltrials.gov) - Jan 31, 2013
P3, N=129, Completed, Sponsor: Otsuka Pakistan Limited
Recruiting --> Completed Initiation date: Jun 2010 --> Oct 2010
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion, Combination therapy: MGES: Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation (clinicaltrials.gov) - Jan 31, 2013
P3, N=129, Completed, Sponsor: Otsuka Pakistan Limited
Initiation date: Jun 2010 --> Oct 2010 Not yet recruiting --> Completed
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
New P1 trial: The Pharmacokinetic Interaction Between Celecoxib and Rebamipide (clinicaltrials.gov) - Mar 6, 2012
P1, N=30, Not yet recruiting, Sponsor: Hanlim Pharm. Co., Ltd.
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: PRESENT: PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity (clinicaltrials.gov) - Nov 14, 2011
P3, N=396, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Not yet recruiting --> Completed Recruiting --> Completed